Kanuma

 

Active substance

sebelipase alfa

Holder

Alexion Pharma International Trading

Status

Running

Indication

treatment of paediatric and adult patients with lysosomal acid lipase deficiency (LAL-D) who participated to the open label phase 2 study (LAL-C06)

Public documents 

Approbation

Information for the patient

CInformed consent

Last update

05/07/2021

Last updated on 30/08/2021